Skip to main content
NUTRITION 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Food Science and Nutrition (Poster Session)

(P09-006-24) Tissue Specific Delivery of Dietary Metabolite Phenolic Acids Using Clostridial Collagenase Collagen Binding Domain

Sunday, June 30, 2024
11:45 AM – 12:45 PM CT
Location: Poster Board 284

    Presenting Author(s)

  • PC

    Perry Caviness, PhD

    Postdoctoral Researcher
    Arkansas Children's Nutrition Center
    LITTLE ROCK, Arkansas, United States

    • Co-Author(s)

  • OL

    Oxana P. Lazarenko, M.D.

    Arkansas Children's Nutrition Center
    Little Rock, Arkansas, United States

  • MB

    Michael Blackburn, Phd

    Arkansas Children's Nutrition Center / University of Arkansas for Medical Sciences
    Little Rock, Arkansas, United States

  • JC

    Jin-Ran Chen, Phd

    Associate Professor
    Arkansas Children's Nutrition Center / University of Arkansas for Medical Sciences
    Little Rock, Arkansas, United States

Disclosure(s):
Perry Caviness, PhD: No relevant financial relationship(s) with ineligible companies to disclose.


Objectives: Dietary metabolites of phenolic acids, hippuric acid (HA) and 3-(3-hydroxyphenyl) propionic acid (3-3-PPA), suppress bone resorption and show potential as novel anti-bone resorption therapeutics. To avoid potential degradation, HA and 3-3-PPA were cross-linked to Clostridial collagenase collagen binding domain (CBD) and the ability of cross-linked HA or 3-3-PPA (HA-CBD or 3-3-PPA-CBD) to specifically target bone was investigated in mouse models. In addition, HA-CBD/3-3-PPA-CBD activities on bone cells were determined and HA or 3-3-PPA epigenetic effects on bone were investigated.

Methods: HA or 3-3-PPA were crosslinked to CBD using EDC/NHS crosslinker and modification was confirmed with proteomics. Additionally prior to injection into pregnant mouse model, N-terminal Cys of HA-CBD/3-3-PPA-CBD was conjugated with Alexa Fluor 488 dye. After 4 hr., mice were sacrificed, bone tissue was collected from both dams and fetus, decalcified using EDTA, prepared for histology and observed under an epifluorescent microscope.

Results: HA-CBD/3-3-PPA CBD were shown to be as effective at suppressing osteoclastogenesis as unconjugated HA/3-3-PPA. In pregnant mice, HA-CBD/3-3-PPA-CBD localized in dam tibia and fetal calvaria. Bone marrow cells (BMC) and bone marrow plasma (BMP) from dams showed an increase in HA following HA-CBD injection (BMC, Control: 1.76 µmole HA/µg cell lysate, HA-CBD: 2.16 µmole HA/µg cell lysate; BMP, Control: 0.68 µmole/µg cell lysate, HA-CBD: 1.36 µmole/µg cell lysate). Osteoclast promoting genes, MMP9 and Cav1, were suppressed in Raw 264.7 cells following HA-CBD/3-3-PPA-CBD treatment. Investigation into HA/3-3-PPA mechanism, revealed that DNA methylation (%5-mC) is decreased following HA or 3-3-PPA treatment and %5-mC levels have a strong negative correlation with bone volume (R = -0.506). In addition, NADPH levels in Raw 264.7 cells were suppressed following HA/3-3-PPA treatment.

Conclusions: In pregnant mice, HA-CBD/3-3-PPA-CBD localized to bone tissue in both dam and fetus, showing an ability to cross the placental barrier and impact maternal and fetal bone tissue. In addition, HA/3-3-PPA induced decrease in %5-mC was negatively correlated with bone volume, suggesting these dietary metabolites epigenetically regulated bone development.

Funding Sources: This study is supported by funds from the USDA-ARS and NIH.